Results

The expansion of MDsCs During Mammary Tumor Growth in Mice with Deleted TbRII
We have previously shown that conditional knockout of TRII in mammary epithelial cells of MMTV-PyMT mice results in shortened tumor latency and an increased number of metastases intRoduction TGF- plays a major role in the regulation of tumor initiation, progression, and metastasis and requires the type II TGF- receptor (TRII) for signaling. It has been shown that decreased expression of TRII is correlated with an increased risk of developing invasive breast cancer (1) and that loss of TRII is correlated with high-grade human carcinoma in situ and invasive breast cancer (2) . In our laboratory, we have shown that conditional deletion of TRII in mammary epithelial cells that also express the polyoma middle T (PyMT) oncogene under control of the mouse mammary tumor virus (MMTV) promoter resulted in shortened tumor latency and a 5-fold increase in lung metastases compared with PyMT tumors with intact TGF- signaling (3, 4) . We identified that TGF- signaling mediates intrinsic, stromalepithelial, and host-tumor interactions during breast cancer progression by regulating basal CXC chemokine ligand 1, CXC chemokine ligand 5 (CXCL1/5), and CC chemokine ligand 20 expression (5) .
Interleukin (IL)-17 is a cytokine secreted by CD4 and CD8 cells (6) (7) (8) . The differentiation and regulation of murine Th17 cells has been extensively studied in the past few www.aacrjournals.org Novitskiy et al.
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Tgfbr2 KO mice (Fig. 1A, Supplementary Fig. S1 ). Localization of CD11b + Gr1 + cells in the tumor tissue was similar to our previously published studies (data not shown) (19) . Surprisingly, we found that CD11b + Gr1 + cells are negative for CXCR2 in lung and tumor tissues but positive in the spleen and bone marrow (Fig. 1B-C) . We have previously shown that SDF-1/CXCR4 and CXCL5/CXCR2 are involved in the recruitment of MDSCs into tumors of PyMT/Tgfbr2 KO mice (19) . Therefore, we concentrated our studies on mechanisms driving the migration of MDSCs to tumor tissue, which are recruited by CXCL1/5.
TGF-b Regulates IL-17-stimulated secretion of CXCL1/5 in Carcinoma Cells
CXCL1/5 are the primary chemokines that signal through CXCR2 to induce myeloid cell chemotaxis. However, it is interesting that CXCR2 is not expressed in CD11b + Gr1 + cells found in the tumor tissue. To address this issue, we in the lung (3, 4) . In addition, we reported that 1 week after tumor palpation, the number of CD11b (Fig. 1A, Supplementary Fig. S1 ) except at a late stage of tumor progression (day 28).
In the lungs of these tumor-bearing animals we found increased numbers of these cells on days 7, 14, and 21 of tumor progression in PyMT/Tgfbr2 KO mice. No differences were found in the bone marrow of these mice. In parallel with the increased number of CD11b Fig. S2 ) and incubated in the presence of IL-17 with or without TGF-. Reinforcing previous work performed with the use of cultured cell lines, we found that these sorted epithelial cells displayed the same profile of CXCL1/5 chemokine expression (Fig. 2C) .
Incubation with IL-17 increased secretion of CXCL1/5 from both types of tumor cells with a more intense increase in CXCL5. Importantly, we observed that TGF- completely inhibits IL-17-stimulated secretion of CXCL1/5 from PyMT/ isolated CD11b + Gr1 + cells from the spleen of tumor-bearing mice and incubated these cells with varying concentrations of CXCL1/5. We observed a significant decrease in expression of CXCR2 starting at a concentration of 10 ng/ mL. Incubation with greater concentrations of chemokines resulted in an almost complete loss of CXCR2 expression (Fig.  1D) . As seen previously with CXCL5 (19) , loss of TRII in PyMT tumor cell lines resulted in an increased secretion of CXCL1 ( Fig.  2A) . Moreover, the significantly high level of CXCL1 secretion indicates a potentially important role in the induction of MDSCs chemotaxis. These data are further supported by the analysis of CXCL1/5 in tumor explants in which we also found an increased level of CXCL1/5 in PyMT/Tgfbr2 KO mice (Fig. 2B) . 5 /mL) and splenocytes were incubated for 24 hours in 3 mL of DMEM, 5% FBS. The level of chemokines was measured by ELISA in conditional medium. B, tumor explant was prepared as described in the Methods and analyzed for CXCL1 and CXCL5 by ELISA (R&D Systems). Data correspond to the mean ± SEM of 3 individual mice from 3 experiments. C, sorted carcinoma cells from freshly isolated tumor tissue (1.5 × 10 5 /mL) were incubated for 24 hours in 1 mL of DMEM, 5% FBS. Level of CXCL1/5 was measured by ELISA in conditional medium. IL-17 was used at a concentration of 10 ng/mL and TGF- at a concentration 1 ng/mL. D, cultured tumor epithelial cells were stained with IL-17Ra/CD217-PE. Cells were analyzed on FACSCalibur. Representative FACS plot is showing from 3 experiments. e, cultured carcinoma cells (2.5 × 10 4 cells/mL) were incubated with IL-17A concentrations from 0 to 50 ng/ mL. Data correspond to the mean from 3 experiments. Conditioned medium was analyzed by ELISA (R&D Systems). EC 50 was analyzed by GraphPad Prism software. *P < 0.05, **P < 0.01. PyMT/Tgfbr2 fl is Tgfbr2 FL , PyMT/Tgfbr2 KO is Tgfbr2 KO . Data correspond to the mean ± SEM. IL-17R is the primary receptor for IL-17 signaling (7) and because of the more robust response of PyMT/Tgfbr2 KO cells to IL-17 stimulation, alterations in IL-17R expression (CD217) caused by the loss of TRII expression were examined. Increased expression of CD217 was observed on PyMT/ Tgfbr2 KO cells (Fig. 2D) . After incubating cells with varying concentrations of IL-17, we found that PyMT/Tgfbr2 KO carcinoma cells are more sensitive to IL-17, resulting in enhanced secretion of CXCL1/5 (Fig. 2E ). Additional analysis showed that PyMT/Tgfbr2 KO cells are 4 times more sensitive to low concentrations of IL-17 (50 pg/mL) in stimulation of CXCL1/5 secretion (data not shown).
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Deletion of TRII in carcinoma cells displayed a double effect on CXCL1/5 secretion. First, deletion of TRII increased expression of CD217 and as a consequence sensitized carcinoma cells to IL-17, and second, deletion of TRII prevented inhibition by TGF- of IL-17-stimulated secretion of chemokines.
Deletion of TbRII in Carcinoma Cells Increases the Number of Th17 Cells
The presence of IL-6, TGF-, and IL-23 preferentially promotes differentiation of CD4 with the use of freshly resected and PBS-perfused tissues (to avoid contamination from circulating cells), and these data correlated with our data shown in Figure 3E ( Supplementary  Fig. S3A ).
In addition, we sorted MDSCs and TAMs from tumor tissue ( Supplementary Fig. S3B ) and analyzed the expression of the IL-6, IL-23 (p19), and TGF- genes by RT-PCR. Previously, it has been shown that MDSCs are a major source of TGF- in PyMT/Tgfbr2 KO tumors (19) . Analysis of MDSCs from tumor tissue recapitulated these findings (Fig. 3B) Fig. S3C ). Similar results were obtained by the use of another tumor model, 4T1 mammary carcinoma cells, which produce more CXCL1/5 than PyMT/Tgfbr2 KO carcinoma cells (Supplementary Fig. S4 ). Quantitative analysis of the proportion of CD4 + IL17A + cells to the total number of CD4 + cells showed that PyMT/Tgfbr2 KO tumors contain on average 3.5 times more Th17 cells and also CD4 + T cells isolated from knockout tumors produced more IL-17s (Fig. 3C ).
IL-17 Increases the Protumorigenic Properties of MDsCs and Monocytes
Because we found that the number of Th17 cells in tumor tissue is increased in PyMT/Tgfbr2 KO mice, we hypothesized that myeloid cells from tumor tissue of these mice have increased expression of protumorigenic genes as the result of the increased presence of IL-17. First, we checked the possible role of IL-17 in functions of myeloid cells. We incubated MDSCs with IL-17 and found an up-regulation in the expression of genes that correlated with the suppressive function of MDSCs, such as Arg, matrix metalloproteinase (MMP)-9, IDO, cyclooxygenase (COX)-2, and MMP-13 (Fig. 3D ). An increased suppressive function of MDSCs on T-cell proliferation also was observed after incubation with IL-17 ( Supplementary Fig. S3D ). In monocytes we found that IL-17 up-regulates gene expression corresponding to the M2 type of TAMs, such as VEGF, IL-10, IL-6, Arg, and IDO (Fig. 3D) . Second, we sorted MDSCs and TAMs from tumor tissue and analyzed gene expression. We found that MDSCs from PyMT/ Tgfbr2 KO mice exhibited increased Arg, MMP-13, and TGF- expression, whereas TAMs from these mice exhibited increased Arg, MMP-9, and IL-1 expression compared with PyMT/ Tgfbr2 fl mice (Fig. 3E) 
ReseaRCh aRTICLe Neutralization of IL-17 Decreases Tumor Growth and Number of Metastasis
Osmotic pumps were implanted on the day of tumor palpation with anti-IL-17 Ab or with Rat IgG for the control group. After 2 weeks, the osmotic pumps were removed and the tumors were allowed to develop for an additional 2 weeks. On the 28th day after tumor palpation, analysis of tumor size, immune cell infiltration, and metastasis was performed (Fig. 4) . It was found that treatment with anti-IL-17 Ab decreased tumor growth (Fig.  4B) (Fig. 4C) . One possible explanation for the significant decrease in the MDSC population could be decreased secretion of CXCL1/5 from carcinoma cells, which can be stimulated by IL-17. To evaluate this hypothesis, the level of CXCL1 was measured in tumor tissue lysates, and a significant decrease in CXCL1 expression in PyMT/Tgbr2 KO mice after treatment with anti-IL-17 Ab was observed (Fig. 4D) . Flow cytometry analysis showed a decreased percentage of CD11b (Fig. 4E ). In addition we sorted MDSCs from tumor tissues of PyMT/Tgfbr2 KO mice and found decreased expression of the Arg, MMP-13, and TGF- genes, which are the primary mediators of the suppressive function of MDSCs (Fig.  4F) . Taken together, these data indicate that IL-17 plays a major role in tumor progression, through the modulation of MDSC migration and function, and the effect of IL-17 is increased in mice with deleted TRII in carcinoma cells.
Importance of IL-17 in human Breast Cancers
To determine the relevance of these findings to human breast cancer, we analyzed microarray profiles of human breast cancer tissues with well-documented clinical data related to lymph node (LN) involvement, estrogen receptor (ER) status, and time of relapse detection during a 10-year period. In a mouse model, we found that deletion of TRII in epithelial cells correlated with increased Th17 response. Therefore, we first conducted a correlation analysis between expression of genes from TGF- signaling and genes that associated with Th17 response. We found that only 2 Th17 genes had a significant correlation with TGF- superfamily genes IL-17A and IL-17F (data not shown). A large number of genes associated with TGF- signaling had a negative correlation with IL-17A/F (data not shown).
Second, we analyzed the correlation between IL-17 and the CXCL1/5 genes and found a very strong positive correlation between IL-17A and CXCL1 and IL-17A and CXCL5 (r 5 0.25, P = 0.0001 and r = 0.22, P = 0.0007, respectively; also, there is a marginal effect between IL-17RA/CXCL1 [r = 0.12, P = 0.07] and IL-17RC/CXCL5 [r = 0.12, P = 0.07]). These findings indicate that in human breast cancer, as well as in mouse models, decreased TGF- signaling is correlated with increased CXCL1/5 genes and Th17 response.
Next, we examined the association of Th17 genes with tumor subtype and relapse-free survival (RFS) by testing whether LN status and ER status would modify the association (Fig.  5) . Three genes from Th17 family had a significant interaction with RFS: IL-17RC, IL17RA, and IL-17F. IL17-RC was associated Our data suggest that some particular genes in human breast cancer may correlate with Th17 response and associate with reduced RFS in subsets of breast cancer patients. The nonsignificant correlations or marginal effects may be attributable to the lack of study power or the heterogeneity of the human data, and we conclude that further testing in larger human data sets may be necessary to confirm that our findings have a direct impact on the patient population. Collectively, our findings indicate a strategy for targeting tumor growth and tumor metastasis by disrupting Th17 cell development in selected breast cancer cases.
discussion
An important role of MDSCs in tumor-associated immune response has been established in a large number of studies. Here, we have shown the important role of TGF- signaling in carcinoma cells in the stimulation of MDSC migration to the tumor site and enhanced protumorigenic properties of these cells through increased numbers of Th17 cells. We found significantly increased numbers of MDSCs in spleen, bone marrow, lung, and tumor tissue during the course of tumor progression. The role of MDSCs in metastasis initiation and formation has been well established (19) (20) (21) (22) . We suggest that the presence of increased MDSCs in both the tumor and lung of PyMT/Tgfbr2 KO mice is a basic mechanism of acceleration of tumor growth and increased lung metastasis.
Previously, we found that MDSCs in tumor tissue can express high levels of CXCR4 in PyMT/Tgfbr2 KO mice (19) . In this study we found that CD11b + Gr1 + cells from tumor and lung did not express CXCR2. In vitro analysis of MDSCs indicates that CXCR2 is internalized as cells migrate to areas with a high concentration of CXCL1 and/or CXCL5. We suggest that the high level of CXCL1/5 secretion is the primary cause for CXCR2 internalization by tumor infiltrating MDSCs, and this finding suggests that CXCL1/5-CXCR2 axis plays a major role in the recruitment of MDSCs into tumor tissue.
Secretion of the CXCL1/5 chemokines can be induced by IL-1, LPS, TNF-α (23), prostaglandin E2 (24), adenosine (25) , IL-17 (12) , and other factors.
In parallel with increasing production of CXCL chemokines, IL-17 increases the local production of chemokines such as IL-8 (26) and MCP-1 (27) , thereby promoting the recruitment of myeloid cells (28) . In this study, we demonstrated that IL-17 stimulates secretion of CXCL1/5 from carcinoma cells, but TGF- inhibits IL-17-stimulated secretion from carcinoma cells with an intact TGF- signaling pathway. This finding indicates an important role of TRII in regulation of IL-17-stimulated secretion of chemokines. Moreover, we suggest that signaling through TRII regulates expression of CD217 and sensitivity to IL-17 in tumor cells.
Although IL-17 production is increased in inflammatory reactions and is considered to be an inflammatory cytokinepromoting factor in tumor development (29, 30 (18) showed that IL-17 is required for the development of MDSCs in tumor-bearing mice. By using IL-17R
-/-mice and Ad-IL-17 mice, they showed that IL-17 can regulate expression of Arg-I, A100/A8/A9, and MMP9 molecules (18) , which are known to be mediators of MDSC-mediated immunosuppression and tumor promotion (31, 32) . However, this effect could be attributable to the systemic effects of loss or gain of IL-17 function.
In this study, by using a different approach, we showed that IL-17 increases expression of Arg, MMP-9, IDO, COX-2, and MMP-13 (Fig. 4) . Furthermore, after incubating MDSCs with IL-17, these cells have a significantly increased immunosuppressive effect on T-cell proliferation. Also, we found that IL-17 up-regulates gene expression corresponding to M2 type TAMs. Recent work by DeNardo and colleagues (33) using the same mouse model as in our work, but with intact TGF- signaling, showed an important role for T cells in tumor progression. IL-4 secreted by Th2 cells can switch the phenotype of TAMs from M1 to M2. Moreover, they showed that activation of TAMs by IL-4, in combination with factors derived from mammary epithelial cells (MEC), such as SDF1, regulates expression of EGF, which in turn stimulates EGFRinduced MEC invasive behavior in vitro and MEC entry into peripheral blood and pulmonary metastasis in vivo.
We found additional mechanisms in mammary tumor progression in mice with the loss of TGF- signaling in carcinoma cells. The early stages of carcinoma progression are dependent on Th17 cells, which secrete IL-17 to switch the phenotype of TAMs to M2 and increase the number and suppressive activity of to 34th day of age. For additional experiments, 8-to 10-week-old female C57bl/6 and FVB mice were purchased from Harlan Inc. To examine the effect of neutralizing IL-17 on tumor growth, mice were implanted with osmotic pumps (DURECT Corporation) with normal rat IgG or rat anti-mouse IL-17 mAb (600 ng/hr for 2 weeks; R&D Systems). Pumps were implanted on day of tumor palpation and removed after 2 weeks. The studies were approved by IACUC at Vanderbilt University Medical Center.
Flow Cytometry Analysis
Single-cell suspensions were made from spleens, bone marrow, and lungs of normal and tumor-bearing mice (25, 36) , and tumor tissues (37) . These cells were labeled with fluorescence-conjugated Abs (Biolegend; eBiosciense, BD) and isotype-matched IgG controls. The cells were analyzed on LSRII flow cytometry (Becton Dickinson) and the data were analyzed with FlowJo software. For intracellular staining, cells were fixed and permeabilized by the use of BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit following the manufacturer's protocol. T cells were stimulated with Dynabeads Mouse T-Activator CD3-CD28 (Invitrogen) or with Leukocyte Activation Cocktail, with BD GolgiPlug (BD) following the manufacturer's protocols.
Magnetic Cell Separation
Tumor-infiltrating host immune cells and T cells were magnetically separated from tumor tissue of mammary gland by use of CD45 or CD4 magnetic microbeads following application protocols of the manufacturer (Miltenyi Biotec).
Single-Cell Sorting
Splenocytes from tumor-bearing mice and single-cell suspensions of tumor tissue were stained with fluorescence-labeled Abs and sorted with a FACSAria flow cytometer (Becton Dickinson). EpCAM 
Whole-Lung Mounting
Mice were sacrificed by anesthetic overdose. Lungs were processed as described (38) . The tumor nodules in lung were then counted.
Functional Assays
T-cell proliferation was measured using a mixed leukocyte reaction. Dendritic cells from C57BL/6 mice were differentiated from bone marrow cells for 6 days with granulocyte macrophage colonystimulating factor (10 ng/mL) and IL-4 (10 ng/mL) in RPMI 1640 medium. T cells from naïve FVB mice were isolated by the use of R&D Systems Mouse T-cell Enrichment columns, according to the manufacturer's protocol. T cells were plated at 10 5 T cells per well in 96-well plates. Each well contained 100,000 T cells, 25,000 MDSCs, and different numbers of dendritic cells. Cells were incubated for 72 hours. 3 [H]-thymidine was then added at 1 μCi per 200 μL of cells per well for an additional 18 hours followed by cell harvesting and radioactivity count by the use of a liquid scintillation counter.
Preparation of Tumor-Conditioned Medium (Explant)
Tumor explants were prepared from freshly isolated tumors. Spontaneous tumors from Tgfbr2 fl and Tgfbr2 KO mice, without ulceration, approximately 1.5 cm in diameter were removed under sterile conditions after euthanizing the mouse. Tumors were minced into pieces <3 mm in diameter and digested in 1 mg/mL Collagenase Type I/Dispase Type II at 37°C for 2 hours. The digested tissue pieces were then pressed through a 70-μm mesh screen to create a single-cell suspension. Cells were washed with PBS and resuspended in DMEM supplemented with 200 U/mL penicillin plus 50 μg/mL streptomycin and 5% FBS. Cells were cultured overnight at 10 7 cells/mL and the cell-free supernatant collected.
with reduced RFS in breast cancer patients; moreover, the strongest association was observed in patients with ER + , specifically within the luminal A subtype (5) . It has also been reported that IL-17 associated with macrophages is increased in LN + grade 3 human breast cancer (34) . Nam and colleagues (14) found increased IL-17 mRNA in stage II and stage III human breast cancer samples compared with normal breast. Langowski and colleagues (35) showed significant up-regulation of IL-23(p19) mRNA in the overwhelming majority of carcinoma samples from various organ types when compared with their adjacent normal tissue. The expression of IL-17 was also found to be significantly elevated in human tumors, consistent with activation of IL-23-induced processes.
On the basis of these findings, we hypothesized that human breast cancer associated with decreased TGF- signaling would also correlate with increased Th17 response. We observed that increased Th17 response in human breast cancer patients correlated with reduced RFS in patients with ER (Fig. 6 ). Our studies provide insights into a novel mechanism by which epithelial TGF- signaling modulates the tumor microenvironment and is involved in tumor progression. The importance of TGF- signaling in tumor progression is irrefutable and has been implicated in a variety of cancers and at numerous stages of tumor progression. Because the effects of pharmacological targeting of the TGF- pathway in vivo on tumor progression remain controversial as a result of the dual roles of TGF- in tumor progression, the targeting of TGF- effects is a viable option. Because IL-17 has protumorigenic effects on breast cancer, the targeting of this cytokine could be considered when it is associated with impaired TGF- signaling in carcinoma cells. KO mice, respectively, established and cultured in DMEM/F12 with 5% adult bovine serum as previously described (5, 19) .
Methods
Cell Lines and Mice
All studies were performed on MMTV-PyMT/Tgfbr2 flox/flox (PyMT/Tgfbr2 fl ) and MMTV-PyMT/Tgfbr2 KO (PyMT/Tgfbr2 KO ) mice, which were established and maintained as described (3) . MMTV-Cre mice were used to delete Tgfbr2 in the mammary epithelium. These mice have pure FVB background and have spontaneous tumor formation of mammary gland on the 28th
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Statistical Analysis
Data were presented as mean ± SEM. Multiple comparisons between treatment groups and control untreated group were performed by the use of 1-way ANOVA followed by the Dunnett procedure for multiplicity adjustment. A 2-group comparison was performed with the use of 2-sample t tests. Correlation analyses for the gene expression between the signatures of interest were performed with data representing 1,319 patients from 4 independent, previously reported studies (Gene Expression Omnibus ID: GSE10886, GSE4922, GSE6532, and GSE2845) (5).
The gene expression was appropriately normalized across all arrays. Gene symbols were assigned with the manufacturer-provided annotation, but the analysis was performed at probe level. The association between RFS and IL17 family was analyzed with the univariate Cox proportional hazard regression model. We examined the modification effect of ER status and node status by testing the interaction between the IL-17 gene and ER or node status by using the multivariate Cox proportional hazard model. When a significant interaction was identified, a Kaplan-Meier survival curve was created for the "high versus low" of the IL-17 gene expression by dichotoming all the samples among the subtype (Fig. 5) . All tests were 2-tailed. All statistical analyses used a P-value cutoff of 0.05 to determine significance. All data analysis for human breast cancer correlation was performed in R (39) .
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